Paul Sableman
According to the company's press release, the deal amount will be up to $1.3 billion. Of these, $1 billion will be paid immediately, while the remaining $300 million will be paid after certain clinical indicators are achieved. The terms were unanimously approved by the Verve Board of Directors.
Earlier, the Financial Times reported on a possible deal, citing sources.
Verve's current market capitalization was about $559 million at the close of trading on Monday.
Earlier this year, Eli Lilly already bought Scorpion Therapeutics for $2.5 billion and SiteOne Therapeutics for $1 billion.
source: ft.com
Earlier, the Financial Times reported on a possible deal, citing sources.
Verve's current market capitalization was about $559 million at the close of trading on Monday.
Earlier this year, Eli Lilly already bought Scorpion Therapeutics for $2.5 billion and SiteOne Therapeutics for $1 billion.
source: ft.com
